Financing ·
On June 11, 2026, Vivos Therapeutics announced its intention to file a registration statement for a proposed rights…
VVOSVivos Therapeutics, Inc.
On June 11, 2026, Vivos Therapeutics announced its intention to file a registration statement for a proposed rights offering. The company plans to distribute transferable subscription rights as a dividend to shareholders. Each right is expected to allow the holder to purchase one share of common stock at an exercise price of the greater of $1.25 or 20% above the market price on the day before the record date. Rights are expected to be exercisable for nine months, with a subsequent nine-month trading right issued upon exercise at a price of the greater of $1.75 or 40% above the market price. The offering is subject to SEC effectiveness and other regulatory conditions. Vivos Therapeutics operates in the healthcare industry and develops medical devices for sleep apnea treatment.